NASDAQ:ZIOP - Ziopharm Oncology Stock Price, Price Target & More

$4.27 -0.07 (-1.61 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close$4.34
Today's Range$4.20 - $4.40
52-Week Range$3.33 - $7.88
Volume776,955 shs
Average Volume1.58 million shs
Market Capitalization$613.74 million
P/E Ratio-8.06
Dividend YieldN/A
Beta1.72

About Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology logoZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, a gene therapy product candidate to treat patients with recurrent glioblastoma. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has collaboration agreements with Precigen, Inc., MD Anderson Cancer Center, the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.

Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ZIOP
CUSIP98973P10
Phone617-259-1970

Debt

Debt-to-Equity RatioN/A
Current Ratio4.35%
Quick Ratio4.35%

Price-To-Earnings

Trailing P/E Ratio-8.06
Forward P/E Ratio-8.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.39 million
Price / Sales95.16
Cash FlowN/A
Price / CashN/A
Book Value($0.68) per share
Price / Book-6.28

Profitability

EPS (Most Recent Fiscal Year)($0.53)
Net Income$-54,320,000.00
Net Margins-928.50%
Return on EquityN/A
Return on Assets-53.51%

Miscellaneous

Employees46
Outstanding Shares142,400,000

How to Become a New Pot Stock Millionaire

Ziopharm Oncology (NASDAQ:ZIOP) Frequently Asked Questions

What is Ziopharm Oncology's stock symbol?

Ziopharm Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How were Ziopharm Oncology's earnings last quarter?

Ziopharm Oncology Inc (NASDAQ:ZIOP) posted its quarterly earnings data on Thursday, March, 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.13). The biotechnology company earned $1.60 million during the quarter, compared to analyst estimates of $1.59 million. Ziopharm Oncology's revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.11) earnings per share. View Ziopharm Oncology's Earnings History.

When is Ziopharm Oncology's next earnings date?

Ziopharm Oncology is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Ziopharm Oncology.

What price target have analysts set for ZIOP?

2 brokerages have issued 1 year target prices for Ziopharm Oncology's shares. Their forecasts range from $10.00 to $10.00. On average, they expect Ziopharm Oncology's share price to reach $10.00 in the next twelve months. View Analyst Ratings for Ziopharm Oncology.

Are investors shorting Ziopharm Oncology?

Ziopharm Oncology saw a increase in short interest in March. As of March 29th, there was short interest totalling 35,871,152 shares, an increase of 1.4% from the March 15th total of 35,375,906 shares. Based on an average daily volume of 1,008,435 shares, the days-to-cover ratio is presently 35.6 days. Approximately 28.2% of the company's shares are sold short.

Who are some of Ziopharm Oncology's key competitors?

Who are Ziopharm Oncology's key executives?

Ziopharm Oncology's management team includes the folowing people:
  • Dr. Laurence James Neil Cooper Ph.D., M.D., Chief Exec. Officer (Age 53)
  • Mr. Kevin G. Lafond, Sr. VP of Fin., CFO, Chief Accounting Officer, Treasurer & Corp. Controller (Age 62)
  • Dr. Francois Lebel M.D., Chief Medical Officer and Exec. VP of R&D (Age 66)
  • Dr. David M. Mauney M.D., Exec. VP, Chief Bus. Officer & Interim COO (Age 49)
  • Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.

Has Ziopharm Oncology been receiving favorable news coverage?

News coverage about ZIOP stock has been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ziopharm Oncology earned a daily sentiment score of 0.22 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.78 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Ziopharm Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ziopharm Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $4.27.

How big of a company is Ziopharm Oncology?

Ziopharm Oncology has a market capitalization of $613.74 million and generates $6.39 million in revenue each year. The biotechnology company earns $-54,320,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. Ziopharm Oncology employs 46 workers across the globe.

How can I contact Ziopharm Oncology?

Ziopharm Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34 NAVY YARD PLAZA, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]


MarketBeat Community Rating for Ziopharm Oncology (ZIOP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  205 (Vote Outperform)
Underperform Votes:  243 (Vote Underperform)
Total Votes:  448
MarketBeat's community ratings are surveys of what our community members think about Ziopharm Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ziopharm Oncology (NASDAQ:ZIOP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Ziopharm Oncology in the last 12 months. Their average twelve-month price target is $10.00, suggesting that the stock has a possible upside of 134.19%. The high price target for ZIOP is $10.00 and the low price target for ZIOP is $10.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$10.00$16.50$16.50
Price Target Upside: 134.19% upside147.52% upside271.62% upside198.37% upside

Ziopharm Oncology (NASDAQ:ZIOP) Consensus Price Target History

Price Target History for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ:ZIOP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/5/2018HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
12/11/2017Raymond JamesReiterated RatingHoldHighView Rating Details
2/28/2017Griffin SecuritiesReiterated RatingBuy$23.00N/AView Rating Details
1/12/2017JPMorgan ChaseReiterated RatingHoldN/AView Rating Details
8/10/2016Wells FargoUpgradeUnderperform -> Market PerformN/AView Rating Details
7/18/2016MizuhoReiterated RatingNeutral$7.00 -> $5.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Ziopharm Oncology (NASDAQ:ZIOP) Earnings History and Estimates Chart

Earnings by Quarter for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ:ZIOP) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.53 EPS
Next Year EPS Consensus Estimate: $-0.52 EPS

Ziopharm Oncology (NASDAQ ZIOP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018        
3/1/2018Q4 2017($0.13)($0.13)$1.59 million$1.60 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.13)($0.13)$1.66 million$1.60 millionViewN/AView Earnings Details
7/31/2017Q2 2017($0.13)($0.13)$1.66 million$1.60 millionViewN/AView Earnings Details
5/1/2017Q1 2017($0.12)($0.15)$1.71 million$1.60 millionViewListenView Earnings Details
2/16/2017Q4 2016($0.11)($0.11)$1.62 million$1.60 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.11)($0.11)$1.45 million$1.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.11)($1.01)$1.52 million$1.70 millionViewN/AView Earnings Details
5/10/2016Q1($0.08)($0.09)$1.89 million$1.97 millionViewN/AView Earnings Details
2/24/2016Q4($0.07)($0.07)$1.82 million$1.92 millionViewN/AView Earnings Details
11/2/2015Q315($0.13)($0.14)$1.19 million$1.90 millionViewN/AView Earnings Details
8/10/2015Q2($0.22)($0.11)$57.70 million$0.27 millionViewN/AView Earnings Details
5/7/2015($0.13)($0.10)$0.20 million$0.30 millionViewN/AView Earnings Details
2/26/2015Q414($0.14)($0.09)$420.00 million$0.34 millionViewN/AView Earnings Details
10/30/2014Q314($0.12)($0.06)$0.20 million$0.63 millionViewN/AView Earnings Details
8/7/2014Q214($0.17)($0.06)$7.50 million$0.20 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.10)$0.20 million$0.20 millionViewN/AView Earnings Details
3/3/2014Q413($0.15)($0.09)$0.20 million$0.20 millionViewN/AView Earnings Details
10/22/2013Q313($0.17)($0.20)$0.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.24)($0.22)$0.20 million$0.20 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.29)($0.48)$0.17 million$0.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details
8/2/2012($0.23)($0.29)ViewN/AView Earnings Details
5/3/2012($0.22)($0.25)ViewN/AView Earnings Details
2/29/2012($0.23)($0.24)ViewN/AView Earnings Details
11/3/2011($0.28)($0.01)ViewN/AView Earnings Details
8/1/2011($0.23)($0.16)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.17)($0.18)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.25)($0.25)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.17)($0.18)ViewN/AView Earnings Details
7/30/2010Q2 2010($0.13)$0.19ViewN/AView Earnings Details
4/30/2010Q1 2010($0.10)($0.11)ViewN/AView Earnings Details
3/18/2010Q4 2009($0.12)$0.03ViewN/AView Earnings Details
11/11/2009Q3 2009($0.13)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.10)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.16)ViewN/AView Earnings Details
3/24/2009Q4 2008($0.19)($0.21)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.23)($0.26)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.36)($0.31)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.35)($0.41)ViewN/AView Earnings Details
2/22/2008Q4 2007($0.39)($0.36)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ziopharm Oncology (NASDAQ:ZIOP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ziopharm Oncology (NASDAQ ZIOP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 40.09%
Insider Trading History for Ziopharm Oncology (NASDAQ:ZIOP)
Institutional Ownership by Quarter for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ ZIOP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2017David M Md MauneyEVPBuy4,270$4.68$19,983.6058,662View SEC Filing  
11/8/2017Laurence James Neil CooperCEOBuy6,440$4.68$30,139.201,083,731View SEC Filing  
6/4/2015Murray BrennanDirectorSell40,000$9.70$388,000.00View SEC Filing  
2/9/2015Randal J KirkDirectorBuy1,440,000$8.75$12,600,000.00View SEC Filing  
10/29/2013Randal J KirkDirectorBuy2,857,143$3.50$10,000,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ziopharm Oncology (NASDAQ ZIOP) News Headlines

Source:
DateHeadline
Ziopharm Oncology (ZIOP) Lowered to "Sell" at BidaskClubZiopharm Oncology (ZIOP) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - April 19 at 10:42 AM
 Brokerages Anticipate Ziopharm Oncology Inc (ZIOP) Will Announce Quarterly Sales of $1.55 Million Brokerages Anticipate Ziopharm Oncology Inc (ZIOP) Will Announce Quarterly Sales of $1.55 Million
www.americanbankingnews.com - April 19 at 2:28 AM
Ziopharm Oncology (ZIOP) Stock Rating Upgraded by ValuEngineZiopharm Oncology (ZIOP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 17 at 10:21 PM
-$0.13 EPS Expected for Ziopharm Oncology Inc (ZIOP) This Quarter-$0.13 EPS Expected for Ziopharm Oncology Inc (ZIOP) This Quarter
www.americanbankingnews.com - April 17 at 7:27 PM
Ziopharm Oncology (ZIOP) Given a $10.00 Price Target at HC WainwrightZiopharm Oncology (ZIOP) Given a $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 14 at 3:36 PM
Ziopharm Oncology (ZIOP) Raised to Hold at BidaskClubZiopharm Oncology (ZIOP) Raised to Hold at BidaskClub
www.americanbankingnews.com - April 13 at 9:39 AM
Ziopharm Oncology (ZIOP) Downgraded by ValuEngine to SellZiopharm Oncology (ZIOP) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 10 at 4:28 PM
Ziopharm Oncology (ZIOP) Stock Rating Upgraded by BidaskClubZiopharm Oncology (ZIOP) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
Global Melanoma Therapeutics Market Opportunities 2018: AstraZeneca, Novartis AG, Ziopharm Oncology, Celgene CorporationGlobal Melanoma Therapeutics Market Opportunities 2018: AstraZeneca, Novartis AG, Ziopharm Oncology, Celgene Corporation
www.marketwatch.com - April 4 at 5:22 PM
ZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.55 MillionZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.55 Million
www.americanbankingnews.com - April 2 at 2:12 AM
Edited Transcript of ZIOP earnings conference call or presentation 1-Mar-18 9:30pm GMTEdited Transcript of ZIOP earnings conference call or presentation 1-Mar-18 9:30pm GMT
finance.yahoo.com - April 1 at 9:51 AM
Zacks: Analysts Expect ZIOPHARM Oncology Inc. (ZIOP) Will Post Earnings of -$0.13 Per ShareZacks: Analysts Expect ZIOPHARM Oncology Inc. (ZIOP) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - March 31 at 7:12 PM
ZIOPHARM Oncology (ZIOP) Rating Increased to Sell at BidaskClubZIOPHARM Oncology (ZIOP) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 30 at 5:08 PM
Financial Analysis: ZIOPHARM Oncology (ZIOP) vs. Immune Design (IMDZ)Financial Analysis: ZIOPHARM Oncology (ZIOP) vs. Immune Design (IMDZ)
www.americanbankingnews.com - March 23 at 7:08 PM
ZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.53 MillionZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.53 Million
www.americanbankingnews.com - March 16 at 3:44 AM
Zacks Investment Research Downgrades ZIOPHARM Oncology (ZIOP) to SellZacks Investment Research Downgrades ZIOPHARM Oncology (ZIOP) to Sell
www.americanbankingnews.com - March 15 at 12:50 PM
-$0.13 EPS Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter-$0.13 EPS Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter
www.americanbankingnews.com - March 14 at 5:24 PM
Short Interest in ZIOPHARM Oncology Inc. (ZIOP) Declines By 3.7%Short Interest in ZIOPHARM Oncology Inc. (ZIOP) Declines By 3.7%
www.americanbankingnews.com - March 12 at 2:14 AM
ZIOPHARM Oncology (ZIOP) Raised to "Hold" at Zacks Investment ResearchZIOPHARM Oncology (ZIOP) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 9 at 9:02 PM
ZIOPHARM Oncology, Inc. 2017 Q4 - Results - Earnings Call SlidesZIOPHARM Oncology, Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - March 5 at 4:25 PM
ZIOPHARM Oncology (ZIOP) Earns Buy Rating from HC WainwrightZIOPHARM Oncology (ZIOP) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - March 5 at 11:48 AM
ZIOPHARM Oncology (ZIOP) Rating Lowered to Sell at Zacks Investment ResearchZIOPHARM Oncology (ZIOP) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 3 at 12:00 PM
Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues BeatIntrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - March 2 at 4:13 PM
ZIOPHARM Oncology (ZIOP) Downgraded to "Strong Sell" at ValuEngineZIOPHARM Oncology (ZIOP) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 1 at 11:30 PM
ZIOPHARM Oncology (ZIOP) Announces  Earnings ResultsZIOPHARM Oncology (ZIOP) Announces Earnings Results
www.americanbankingnews.com - March 1 at 9:12 PM
Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateZiopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 1 at 4:19 PM
ZIOPHARM Oncology Inc. (ZIOP) Sees Large Growth in Short InterestZIOPHARM Oncology Inc. (ZIOP) Sees Large Growth in Short Interest
www.americanbankingnews.com - March 1 at 2:40 AM
ZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.59 MillionZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.59 Million
www.americanbankingnews.com - February 27 at 4:16 AM
 Brokerages Expect ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 EPS Brokerages Expect ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 EPS
www.americanbankingnews.com - February 25 at 5:17 PM
ZIOPHARM Oncology (ZIOP) Set to Announce Quarterly Earnings on ThursdayZIOPHARM Oncology (ZIOP) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - February 22 at 2:32 AM
ZIOPHARM Oncology Inc. (ZIOP) Given Consensus Recommendation of "Hold" by BrokeragesZIOPHARM Oncology Inc. (ZIOP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 18 at 1:30 AM
Wired News – Ziopharm Oncology Presents Data on Rapid Production of CAR T Cells at Keystone SymposiaWired News – Ziopharm Oncology Presents Data on Rapid Production of CAR T Cells at Keystone Symposia
finance.yahoo.com - February 14 at 3:23 PM
Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference ... - GlobeNewswire (press release)Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 3:21 PM
Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1
finance.yahoo.com - February 13 at 3:21 PM
Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular ... - GlobeNewswire (press release)Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 6:14 AM
Pre-Open Movers 02/12: (CSRA) (HGSH) (COLL) Higher; (AXON) (SPNS) (LJPC) Lower (more...)Pre-Open Movers 02/12: (CSRA) (HGSH) (COLL) Higher; (AXON) (SPNS) (LJPC) Lower (more...)
www.streetinsider.com - February 12 at 3:21 PM
ZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.59 MillionZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.59 Million
www.americanbankingnews.com - February 11 at 6:50 AM
ZIOPHARM Oncology Inc. (ZIOP) Short Interest Down 5.9% in JanuaryZIOPHARM Oncology Inc. (ZIOP) Short Interest Down 5.9% in January
www.americanbankingnews.com - February 10 at 1:40 AM
Ziopharm stock rallies after company says nothing to see here, folks - MarketWatchZiopharm stock rallies after company says nothing to see here, folks - MarketWatch
www.marketwatch.com - February 7 at 6:10 AM
Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 GuidanceZiopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance
finance.yahoo.com - February 6 at 3:21 PM
Ziopharm stock rallies after company says nothing to see here, folksZiopharm stock rallies after company says nothing to see here, folks
finance.yahoo.com - February 6 at 3:21 PM
Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM ... - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM ... - PR Newswire (press release)
www.prnewswire.com - February 2 at 3:22 PM
ZIOPHARM Oncology Inc. (ZIOP) Receives Average Recommendation of "Hold" from AnalystsZIOPHARM Oncology Inc. (ZIOP) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 24 at 1:44 AM
Did ZIOPHARM Oncology Inc’s (NASDAQ:ZIOP) Earnings Growth Outperform The Industry?Did ZIOPHARM Oncology Inc’s (NASDAQ:ZIOP) Earnings Growth Outperform The Industry?
finance.yahoo.com - January 23 at 9:32 AM
Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and ZIOPHARM OncologyToday’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and ZIOPHARM Oncology
finance.yahoo.com - January 23 at 9:32 AM
Reviewing Allena Pharmaceuticals (ALNA) & ZIOPHARM Oncology (ZIOP)Reviewing Allena Pharmaceuticals (ALNA) & ZIOPHARM Oncology (ZIOP)
www.americanbankingnews.com - January 23 at 1:18 AM
Zacks: Brokerages Anticipate ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 Earnings Per ShareZacks: Brokerages Anticipate ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 Earnings Per Share
www.americanbankingnews.com - January 23 at 1:18 AM
ZIOPHARM Oncology (ZIOP) Stock Rating Reaffirmed by Zacks Investment ResearchZIOPHARM Oncology (ZIOP) Stock Rating Reaffirmed by Zacks Investment Research
www.americanbankingnews.com - January 13 at 4:08 PM
BidaskClub Downgrades ZIOPHARM Oncology (ZIOP) to Strong SellBidaskClub Downgrades ZIOPHARM Oncology (ZIOP) to Strong Sell
www.americanbankingnews.com - January 12 at 12:40 AM
Active-Investors: Blog Exposure - ZIOPHARM Updated on Key Clinical Programs and Corporate Development ActivitiesActive-Investors: Blog Exposure - ZIOPHARM Updated on Key Clinical Programs and Corporate Development Activities
www.finanznachrichten.de - January 11 at 11:00 AM

SEC Filings

Ziopharm Oncology (NASDAQ:ZIOP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ziopharm Oncology (NASDAQ:ZIOP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ziopharm Oncology (NASDAQ ZIOP) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.